Gland Pharma reports strong Q2 FY26 performance, revenue up 6%

Gland Pharma Limited reported strong financial results for Q2 FY26, with revenue from operations increasing by 6% year-on-year to ₹14,869 million, and profit after tax (PAT) growing 12% to ₹1,837 million. For the first half of FY26, revenues rose 7% to ₹29,925 million and PAT soared 30% to ₹3,992 million. Gross profit for Q2 FY26 increased 12% year-on-year to ₹9,331 million, while EBITDA grew 6% year-on-year to ₹3,139 million. Consolidated Adjusted EBITDA also saw a significant rise of 13% year-on-year to ₹3,355 million for the quarter.

The company's base business saw a 1% increase in quarterly revenue to ₹10,767 million and a 2% rise in half-yearly revenues to ₹21,176 million. Notably, the USA market's revenue contribution grew 10% year-on-year, and Europe saw a 16% increase, supported by a 21% top-line growth in Cenexi. Research and development (R&D) expenses for Q2 FY26 reached ₹614 million, representing 5.8% of revenue.

Gland Pharma launched seven new molecules in the USA this quarter, including Daptomycin-RTU and Sumatriptan, and filed six abbreviated new drug applications (ANDAs), with five approved. Fifteen products are in co-development, and the company is aggressively expanding its GLP-1/Pen/cartridge capacity from approximately 40 million to 140 million units. Cenexi reported a 21% increase in revenue for Q2 FY26, despite planned shutdowns impacting operations, with production at Fontenay back on track and Hérouville ramping up inactivated vaccine and sterile ophthalmic gel production.